Elizabeth Mumford Galloway, MD | |
3200 Providence Dr, Anchorage, AK 99508-4615 | |
(907) 562-2211 | |
(509) 479-0214 |
Full Name | Elizabeth Mumford Galloway |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 3200 Providence Dr, Anchorage, Alaska |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003023177 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2080P0203X | Pediatrics - Pediatric Critical Care Medicine | 35.085940 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Elizabeth Mumford Galloway, MD Po Box 35145, Lock Box 1084, Seattle, WA 98124-5145 Ph: (866) 776-8150 | Elizabeth Mumford Galloway, MD 3200 Providence Dr, Anchorage, AK 99508-4615 Ph: (907) 562-2211 |
News Archive
China Kanghui Holdings, a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced that the Company's wholly-owned subsidiary, TGM Medical, Inc., has received approvals from the Food and Drug Administration of the United States for its Helicon Hip System ("HHS"), Milestone Knee System ("MKS") and related surgical instruments.
On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.
A large group of researchers from China recently characterized microbial co-infections in the respiratory tract of hospitalized coronavirus disease (COVID-19) patients and demonstrated a high prevalence of both viral and bacterial co-infections – particularly in individuals presenting with severe disease.
SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.
› Verified 8 days ago
Wendy Bailey, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3340 Providence Dr, Suite A-351, Anchorage, AK 99508 Phone: 907-212-4824 Fax: 907-212-4831 | |
Jay D. Johnson, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3801 Lake Otis Pkwy Ste 200, Anchorage, AK 99508 Phone: 907-212-6900 | |
Dr. Stephen Scott Baker, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2841 Debarr Rd, Bldg A, Suite 23, Anchorage, AK 99508 Phone: 907-677-1864 Fax: 907-868-5167 | |
Dr. Rachel Mauryce Kerford Lescher, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4320 Diplomacy Dr, Suite 2300, Anchorage, AK 99508 Phone: 907-729-1000 Fax: 907-729-5244 | |
Dr. James Monroe Nesbitt Jr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3200 Providence Dr, Administration Office, Anchorage, AK 99508 Phone: 907-261-5098 Fax: 907-743-2358 | |
Dr. Emily Margaret Reilly, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-4068 |